These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23100242)

  • 21. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
    Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.
    Möller I; Wintermeyer A; Bender K; Jübner M; Thomas A; Krug O; Schänzer W; Thevis M
    Drug Test Anal; 2011 Sep; 3(9):609-20. PubMed ID: 20872894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis.
    Thevis M; Thomas A; Kohler M; Beuck S; Schänzer W
    J Mass Spectrom; 2009 Apr; 44(4):442-60. PubMed ID: 19373874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls.
    Thevis M; Thomas A; Möller I; Geyer H; Dalton JT; Schänzer W
    Rapid Commun Mass Spectrom; 2011 Aug; 25(15):2187-95. PubMed ID: 21710598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes.
    Thevis M; Thomas A; Fusshöller G; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2010 Aug; 24(15):2245-54. PubMed ID: 20623476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens.
    Thevis M; Gerace E; Thomas A; Beuck S; Geyer H; Schlörer N; Kearbey JD; Dalton JT; Schänzer W
    Drug Test Anal; 2010; 2(11-12):589-98. PubMed ID: 20967890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes.
    Höppner S; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry.
    Ishii H; Leung GN; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2020 Dec; 34(23):e8920. PubMed ID: 32776613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing.
    Schänzer W; Guddat S; Thomas A; Opfermann G; Geyer H; Thevis M
    Drug Test Anal; 2013; 5(11-12):810-8. PubMed ID: 23873860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research.
    Beuck S; Bornatsch W; Lagojda A; Schänzer W; Thevis M
    Drug Test Anal; 2011; 3(11-12):756-70. PubMed ID: 22213684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mass spectrometric characterization of urinary hydrafinil metabolites for routine doping control purposes.
    Knoop A; Fußhöller G; Haenelt N; Goergens C; Guddat S; Geyer H; Thevis M
    Drug Test Anal; 2021 Nov; 13(11-12):1915-1920. PubMed ID: 34378339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503.
    Thevis M; Beuck S; Thomas A; Kortner B; Kohler M; Rodchenkov G; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Apr; 23(8):1139-46. PubMed ID: 19280612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls.
    Sigmund G; Dib J; Tretzel L; Piper T; Bosse C; Schänzer W; Thevis M
    Drug Test Anal; 2015; 7(11-12):1057-62. PubMed ID: 26481102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry.
    de Albuquerque Cavalcanti G; Carius Garrido B; Dias Leal F; Costa Padilha M; Mazzarino M; de la Torre X; Botre F; Radler de Aquino Neto F
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):248-54. PubMed ID: 21924357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach: Potential applications in doping control.
    Kwak YB; Yoon J; Yoo HH
    J Pharm Biomed Anal; 2024 Aug; 246():116190. PubMed ID: 38735208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for benfluorex and its major urinary metabolites in routine doping controls.
    Thevis M; Sigmund G; Gougoulidis V; Beuck S; Schlörer N; Thomas A; Kwiatkowska D; Pokrywka A; Schänzer W
    Anal Bioanal Chem; 2011 Aug; 401(2):543-51. PubMed ID: 21116611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mass spectrometric determination of insulins and their degradation products in sports drug testing.
    Thevis M; Thomas A; Schänzer W
    Mass Spectrom Rev; 2008; 27(1):35-50. PubMed ID: 18000882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mass spectrometric studies on the in vitro generated metabolites of SIRT1 activating drugs for doping control purposes.
    Höppner S; Schänzer W; Thevis M
    J Mass Spectrom; 2013 Jul; 48(7):830-43. PubMed ID: 23832939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
    Thevis M; Thomas A; Geyer H; Schänzer W
    Growth Horm IGF Res; 2014 Dec; 24(6):276-80. PubMed ID: 25466910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of an electrochemically synthesised metabolite of a selective androgen receptor modulator for mass spectrometry-based sports drug testing.
    Thevis M; Lohmann W; Schrader Y; Kohler M; Bornatsch W; Karst U; Schänzer W
    Eur J Mass Spectrom (Chichester); 2008; 14(3):163-70. PubMed ID: 18708696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.